09939 開拓藥業－Ｂ
按盤價 
2.710 +0.030 (+1.119%) 盈利能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 資產回報率 (%) | -46.758% | -22.435% | -72.550% | -46.293% | -42.970% |
| 股東資金回報率 (%) | -83.959% | -41.291% | -108.618% | -60.588% | -53.245% |
| 資本運用回報率 (%) | -93.846% | -44.567% | -164.595% | -54.943% | -45.562% |
邊際利潤分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 毛利率 (%) | 24.598% | -94.600% | N/A | N/A | -- |
| 未計利息、稅項、折舊及攤銷前利潤率 (%) | -509.663% | -2623.000% | N/A | N/A | -2457.246% |
| 稅前邊際利潤率 (%) | -621.012% | -3105.480% | N/A | N/A | -2460.036% |
| 純利率 (%) | -612.285% | -3105.840% | N/A | N/A | -2460.036% |
變現能力分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 流動比率 (X) | 0.433 X | 1.030 X | 2.103 X | 4.740 X | 6.944 X |
| 速動比率 (X) | 0.338 X | 1.017 X | 2.103 X | 2.843 X | 5.345 X |
財務槓桿分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 總負債 / 總資產比率 (%) | 46.423% | 42.911% | 47.297% | 27.246% | 19.963% |
| 總債項 / 總資產比率 (%) | 25.410% | 25.821% | 29.212% | 13.935% | 7.724% |
| 淨債項 / 總資產比率 (%) | 15.804% | -2.797% | -22.040% | -28.158% | -37.254% |
| 總債項 / 股東資金比率 (%) | 47.426% | 45.229% | 55.427% | 19.154% | 9.651% |
| 長期債項 / 股東資金比率 (%) | 0.541% | 6.801% | 29.619% | 12.243% | 9.079% |
| 淨債項 / 股東資金比率 (%) | 29.497% | -4.900% | -41.819% | -38.704% | -46.546% |
| 淨現金 / (債項) ($) | (5.39千萬) | 1.44千萬 | 1.92億 | 5.79億 | 7.70億 |
| 每股淨現金 / (債項) ($) | (0.108) | 0.032 | 0.428 | 1.293 | 1.988 |
| 總債項 / 資本運用比率 (%) | 40.613% | 38.172% | 39.398% | 16.487% | 8.642% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
營運效率分析
| 2025/12 | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| 存貨周轉率日數 (日) | 105.954日 | 83.091日 | N/A | -- | -- |
| 應收貿易帳周轉率日數 (日) | 31.226日 | N/A | N/A | N/A | N/A |
| 應付貿易帳周轉率日數 (日) | 408.081日 | 4473.331日 | N/A | N/A | 1075.706日 |
| 備註： | 即時報價更新時間為21/04/2026 18:00 |
| 港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
| 股東應佔溢利/(虧損) (千) | RMB -200,107 |
| 增長率 | 28.859% |
| 每股盈利/(虧損) | RMB -0.440 |
| 每股帳面資產淨值 (¥) | RMB 0.366 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
